Logo image of LAB

STANDARD BIOTOOLS INC (LAB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:LAB - US34385P1084 - Common Stock

1.28 USD
+0.03 (+2.4%)
Last: 12/31/2025, 8:11:35 PM
1.2738 USD
-0.01 (-0.48%)
After Hours: 12/31/2025, 8:11:35 PM
Fundamental Rating

2

LAB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. The financial health of LAB is average, but there are quite some concerns on its profitability. LAB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LAB had negative earnings in the past year.
In the past year LAB has reported a negative cash flow from operations.
In the past 5 years LAB always reported negative net income.
In the past 5 years LAB always reported negative operating cash flow.
LAB Yearly Net Income VS EBIT VS OCF VS FCFLAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

LAB's Return On Assets of -23.77% is on the low side compared to the rest of the industry. LAB is outperformed by 70.18% of its industry peers.
LAB has a worse Return On Equity (-32.09%) than 61.40% of its industry peers.
Industry RankSector Rank
ROA -23.77%
ROE -32.09%
ROIC N/A
ROA(3y)-34.01%
ROA(5y)-27.97%
ROE(3y)-55.9%
ROE(5y)-53.68%
ROIC(3y)N/A
ROIC(5y)N/A
LAB Yearly ROA, ROE, ROICLAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Gross Margin of LAB (47.94%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of LAB has declined.
The Profit Margin and Operating Margin are not available for LAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.13%
GM growth 5Y-2.51%
LAB Yearly Profit, Operating, Gross MarginsLAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

4

2. Health

2.1 Basic Checks

LAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LAB has been increased compared to 1 year ago.
The number of shares outstanding for LAB has been increased compared to 5 years ago.
Compared to 1 year ago, LAB has an improved debt to assets ratio.
LAB Yearly Shares OutstandingLAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
LAB Yearly Total Debt VS Total AssetsLAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -0.82, we must say that LAB is in the distress zone and has some risk of bankruptcy.
LAB has a worse Altman-Z score (-0.82) than 78.95% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that LAB is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, LAB is in the better half of the industry, outperforming 73.68% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.82
ROIC/WACCN/A
WACC10.92%
LAB Yearly LT Debt VS Equity VS FCFLAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 4.38 indicates that LAB has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.38, LAB is doing good in the industry, outperforming 70.18% of the companies in the same industry.
A Quick Ratio of 4.14 indicates that LAB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.14, LAB is in the better half of the industry, outperforming 75.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.38
Quick Ratio 4.14
LAB Yearly Current Assets VS Current LiabilitesLAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

LAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.11%, which is quite impressive.
Looking at the last year, LAB shows a very negative growth in Revenue. The Revenue has decreased by -17.37% in the last year.
LAB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.28% yearly.
EPS 1Y (TTM)52.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
Revenue 1Y (TTM)-17.37%
Revenue growth 3Y10.13%
Revenue growth 5Y8.28%
Sales Q2Q%-56.52%

3.2 Future

LAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.34% yearly.
Based on estimates for the next years, LAB will show a very negative growth in Revenue. The Revenue will decrease by -16.16% on average per year.
EPS Next Y52.25%
EPS Next 2Y30.97%
EPS Next 3Y20.34%
EPS Next 5YN/A
Revenue Next Year-53.07%
Revenue Next 2Y-31.76%
Revenue Next 3Y-21.36%
Revenue Next 5Y-16.16%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
LAB Yearly Revenue VS EstimatesLAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
LAB Yearly EPS VS EstimatesLAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LAB Price Earnings VS Forward Price EarningsLAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LAB Per share dataLAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

A more expensive valuation may be justified as LAB's earnings are expected to grow with 20.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.97%
EPS Next 3Y20.34%

More info and screens

0

5. Dividend

5.1 Amount

LAB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

STANDARD BIOTOOLS INC

NASDAQ:LAB (12/31/2025, 8:11:35 PM)

After market: 1.2738 -0.01 (-0.48%)

1.28

+0.03 (+2.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners76.69%
Inst Owner ChangeN/A
Ins Owners2.42%
Ins Owner Change25.36%
Market Cap492.25M
Revenue(TTM)128.83M
Net Income(TTM)-128.25M
Analysts77.14
Price Target1.58 (23.44%)
Short Float %2.8%
Short Ratio5.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-36.7%
Min EPS beat(2)-62.02%
Max EPS beat(2)-11.39%
EPS beat(4)1
Avg EPS beat(4)-23.28%
Min EPS beat(4)-62.02%
Max EPS beat(4)7.59%
EPS beat(8)2
Avg EPS beat(8)-42.02%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.94%
Min Revenue beat(2)4.33%
Max Revenue beat(2)7.56%
Revenue beat(4)4
Avg Revenue beat(4)5.02%
Min Revenue beat(4)0.73%
Max Revenue beat(4)7.56%
Revenue beat(8)6
Avg Revenue beat(8)1.89%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-27.27%
EPS NY rev (1m)-18.18%
EPS NY rev (3m)-18.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.19%
Revenue NY rev (1m)-6.96%
Revenue NY rev (3m)-6.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.82
P/FCF N/A
P/OCF N/A
P/B 1.23
P/tB 1.23
EV/EBITDA N/A
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.33
BVpS1.04
TBVpS1.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -23.77%
ROE -32.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.94%
FCFM N/A
ROA(3y)-34.01%
ROA(5y)-27.97%
ROE(3y)-55.9%
ROE(5y)-53.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.13%
GM growth 5Y-2.51%
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 82.18%
Cap/Sales 8.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.38
Quick Ratio 4.14
Altman-Z -0.82
F-Score4
WACC10.92%
ROIC/WACCN/A
Cap/Depr(3y)31.23%
Cap/Depr(5y)51.75%
Cap/Sales(3y)3.79%
Cap/Sales(5y)6.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
EPS Next Y52.25%
EPS Next 2Y30.97%
EPS Next 3Y20.34%
EPS Next 5YN/A
Revenue 1Y (TTM)-17.37%
Revenue growth 3Y10.13%
Revenue growth 5Y8.28%
Sales Q2Q%-56.52%
Revenue Next Year-53.07%
Revenue Next 2Y-31.76%
Revenue Next 3Y-21.36%
Revenue Next 5Y-16.16%
EBIT growth 1Y10.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.04%
EBIT Next 3Y24.99%
EBIT Next 5Y18.51%
FCF growth 1Y-89.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-80.15%
OCF growth 3YN/A
OCF growth 5YN/A

STANDARD BIOTOOLS INC / LAB FAQ

What is the ChartMill fundamental rating of STANDARD BIOTOOLS INC (LAB) stock?

ChartMill assigns a fundamental rating of 2 / 10 to LAB.


Can you provide the valuation status for STANDARD BIOTOOLS INC?

ChartMill assigns a valuation rating of 1 / 10 to STANDARD BIOTOOLS INC (LAB). This can be considered as Overvalued.


Can you provide the profitability details for STANDARD BIOTOOLS INC?

STANDARD BIOTOOLS INC (LAB) has a profitability rating of 0 / 10.


Can you provide the financial health for LAB stock?

The financial health rating of STANDARD BIOTOOLS INC (LAB) is 4 / 10.